Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 7/20 | 0.46 |
| ▸ | CES2 | O00748 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL28072930 | 0.96 | TSHR (0.44) | KMT2AMEN1CES1CES2TSHR | |
| SCHEMBL168007 | 0.85 | CES1 (0.55) | KMT2AMEN1CES1CES2TSHR | |
| Water SCHEMBL27612226 | 0.82 | CES1 (0.52) | KMT2AMEN1CES1CES2TSHR | |
| Hydrochloric Acid SCHEMBL28496848 | 0.82 | CES1 (0.52) | KMT2AMEN1CES1CES2TSHR | |
| Hydrogen Sulfide SCHEMBL28111724 | 0.82 | CES1 (0.52) | KMT2AMEN1CES1CES2TSHR | |
| SCHEMBL312084 | 0.80 | CES1 (0.50) | KMT2AMEN1CES1CES2TSHR | |
| SCHEMBL812709 | 0.80 | KMT2A (0.56) | KMT2AMEN1CES1CES2TSHR | |
| SCHEMBL776222 | 0.79 | ALDH1A1 (0.52) | KMT2AMEN1CES1CES2ALDH1A1 | |
| SCHEMBL11623306 | 0.79 | CES1 (0.48) | KMT2AMEN1CES1CES2TSHR | |
| Hydrochloric Acid SCHEMBL6682457 | 0.78 | KMT2A (0.54) | KMT2AMEN1CES1CES2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989263-B1 | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-01-24 | — | — | US | claimed |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2003-10-23 | — | — | US | claimed |
| WO-2003060098-A2 | METHODS FOR IDENTIFYING COMPOUNDS WHICH INHIBIT BINDING OF NUCLEOCAPSID 7 PROTEIN TO HIV-1 RNA | ACHILLION PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-0782632-B1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | US GOV HEALTH & HUMAN SERV (US) | 2003-04-16 | — | — | EP | claimed |
| US-6001555-A | DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-14 | — | — | US | claimed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | claimed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | claimed |
| CN-117357548-A | Oligonucleotide composition and method for preparing same | 美国杰龙生物医药公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-111228288-B | Oligonucleotide composition and method for preparing same | 美国杰龙生物医药公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3834828-B1 | COMPOSITION COMPRISING A THIAMINE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF VASCULAR OR CARDIAC VALVE CALCIFICATION | KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND (KR) | 2022-06-08 | — | — | EP | disclosed |
| US-20160160178-A1 | IMMUNOTHERAPY USING STEM CELLS | WHITE OAK IND INC (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150125489-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2015-05-07 | — | — | US | disclosed |
| EP-2819696-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2015-01-07 | — | — | EP | disclosed |
| WO-1997044064-A2 | OLIGONUCLEOTIDES WHICH SPECIFICALLY BIND RETROVIRAL NUCLEOCAPSID PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | disclosed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | disclosed |
| US-4119780-A | 2(Isopropyldithio)benzimidazole | MONSANTO COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4006155-A | Method for preparation of phosphorus polysulfides | MONSANTO COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160160178-A1 | IMMUNOTHERAPY USING STEM CELLS | CD14, ICOS, BMP4 | KMT2A 2022/4885MEN1 1157/4885CES1 2138/4885 |
| US-20150125489-A1 | METHOD FOR THE PREPARATION OF DENDRITIC CELL VACCINES | CCR7, CD69, CD14 | KMT2A 4547/4885MEN1 4038/4885CES1 2366/4885 |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | MRPS27, SNRPE, NSUN2 | KMT2A 4492/4885MEN1 4009/4885CES1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.